A Phase 4 interventional study of sirolimus, tacrolimus, mycophenolate mofetil in Kidney Transplantation, sponsored by National Taiwan University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 13 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-03-08.
Sponsored by National Taiwan University Hospital · Phase 4, Interventional, and Prevention
The purpose of this study is to understand whether the pharmacokinetics of tacrolimus is influenced by the concurrent use of sirolimus.
The controlled clinical trial held in NTUH in 2001 revealed that the bioavailability of tacrolimus when combined with sirolimus is lower than that reported in the literature where tacrolimus was not combined with sirolimus. To determine if the difference was due to the drug interaction between sirolimus and tacrolimus, a controlled clinical trial was proposed.
The purpose of this study is to understand whether the pharmacokinetics of tacrolimus is influenced by the concurrent use of sirolimus.
National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The influence of sirolimus on the pharmacokinetics of tacrolimus in renal transplant patients
Compare the outcome of tacrolimus/sirolimus and tacrolimus/mycophenolate in rejection prevention
This study is status unknown, as verified in Aug 2003. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital